Protara Therapeutics, Inc. engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the. treatment of lymphatic malformations. It also develops intravenous choline chloride, an. investigational phospholipid substrate replacement therapy.
Market Cap | 32.224 Million | Shares Outstanding | 11.307 Million | Avg 30-day Volume | 33.129 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.8 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -42.778 Million |
Price to Book Value | 0.0 | Operating Margin | 0.0 | Enterprise Value | 0 |
Current Ratio | 0 | EPS Growth | -0.189 | Quick Ratio | 0 |
1 Yr BETA | 1.0411 | 52-week High/Low | 4.6 / 2.38 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -19.027 | Altman Z-Score | 0.0 | Free Cash Flow to Firm | 1.559 Million |
Earnings Report | 2023-08-08 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
FABBIO PATRICK CHIEF FINANCIAL OFFICER |
|
300,000 | 2023-01-30 | 2 |
ZUMMO JACQUELINE CHF SCIENTIFIC OPERATIONS OFF |
|
210,773 | 2023-01-19 | 3 |
SHEFFERMAN JESSE CEO AND PRESIDENT |
|
1,225,782 | 2023-01-19 | 5 |
BANDARI JATHIN CHIEF MEDICAL OFFICER |
|
163,542 | 2023-01-19 | 3 |
FRY HANNAH VP, CONTROLLER |
|
68,539 | 2023-01-19 | 4 |
|
2,692,594 | 2022-12-30 | 2 | |
DAVIS BLAINE CHIEF FINANCIAL OFFICER |
|
20,662 | 2022-07-15 | 1 |
|
198,000 | 2022-06-30 | 2 | |
|
10,000 | 2022-06-08 | 1 | |
|
10,000 | 2022-06-08 | 1 | |
|
10,000 | 2022-06-08 | 1 | |
|
10,000 | 2022-06-08 | 1 | |
|
10,000 | 2022-06-08 | 1 | |
|
10,000 | 2022-06-08 | 1 | |
|
10,000 | 2022-06-08 | 1 | |
OLIVO MARTIN SEBASTIAN CHIEF MEDICAL OFFICER |
|
14,344 | 2021-06-10 | 0 |
|
No longer subject to file | 2020-09-14 | 0 | |
|
0 | 2020-06-09 | 0 | |
|
2,208,472 | 2020-01-09 | 0 | |
CASOY JULIO CHIEF MEDICAL OFFICER |
|
45,500 | 2020-01-09 | 0 |
|
No longer subject to file | 2019-11-12 | 0 | |
|
No longer subject to file | 2019-11-12 | 0 | |
|
2,175,882 | 2019-11-08 | 0 | |
BURKE STEVEN KEITH SVP AND CHIEF MEDICAL OFFICER |
|
147,248 | 2019-03-15 | 0 |
NOYES TIMOTHY P PRESIDENT AND CEO |
|
0 | 2019-01-31 | 0 |
GOTTLIEB DANIEL PHILIP VP CORPORATE DEVELOPMENT |
|
0 | 2019-01-18 | 0 |
ELDRIDGE, GEORGE ARTHUR SR VP, CFO, TREASR, ASST SECY |
|
0 | 2019-01-18 | 0 |
TONER E. SCOTT SENIOR VP OF COMMERCIAL |
|
0 | 2019-01-18 | 0 |
KOWALSKY MATTHEW PAUL VP, LEGAL AND SECRETARY |
|
0 | 2019-01-18 | 0 |
HARTMAN BRADLEY J VP, PEOPLE |
|
0 | 2019-01-18 | 0 |
|
0 | 2018-06-08 | 0 | |
|
0 | 2018-06-08 | 0 | |
|
0 | 2018-06-08 | 0 | |
|
0 | 2018-06-08 | 0 | |
|
0 | 2018-06-08 | 0 | |
|
0 | 2018-06-08 | 0 | |
|
0 | 2018-06-08 | 0 | |
|
1,224,899 | 2017-11-30 | 0 | |
DEERFIELD PRIVATE DESIGN FUND III, L.P. DEERFIELD SPECIAL SITUATIONS FUND, L.P. DEERFIELD INTERNATIONAL MASTER FUND, L.P. |
|
1,224,899 | 2017-08-02 | 0 |
TVM LIFE SCIENCE VENTURES VI GMBH & CO KG |
|
1,000 | 2017-06-22 | 0 |
|
0 | 2016-06-09 | 0 | |
|
0 | 2015-06-02 | 0 | |
|
0 | 2015-06-02 | 0 | |
DEERFIELD SPECIAL SITUATIONS FUND, L.P. DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P. |
|
No longer subject to file | 2014-10-27 | 0 |
|
3,846,186 | 2014-10-27 | 0 | |
SKYLINE VENTURE PARTNERS QUALIFIED PURCHASER FUND IV L P |
|
1,432,930 | 2014-10-27 | 0 |
|
No longer subject to file | 2014-10-27 | 0 | |
|
1,165,344 | 2014-10-27 | 0 | |
|
0 | 2014-10-21 | 0 | |
|
0 | 2014-10-21 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
PROTARA THERAPEUTIC INC TARA | 2023-06-06 22:15:03 UTC | 3.2725 | 1.7975 | 150000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 21:45:05 UTC | 3.2725 | 1.7975 | 150000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 21:15:04 UTC | 3.2725 | 1.7975 | 150000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 20:45:04 UTC | 3.2725 | 1.7975 | 150000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 20:15:04 UTC | 3.2725 | 1.7975 | 150000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 19:45:04 UTC | 3.2725 | 1.7975 | 150000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 19:15:03 UTC | 3.2725 | 1.7975 | 150000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 18:45:04 UTC | 3.2725 | 1.7975 | 150000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 18:15:04 UTC | 3.2725 | 1.7975 | 150000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 17:45:04 UTC | 3.2725 | 1.7975 | 150000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 17:15:04 UTC | 3.2725 | 1.7975 | 200000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 16:45:04 UTC | 3.2625 | 1.7975 | 200000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 16:15:03 UTC | 3.2625 | 1.7975 | 150000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 15:45:04 UTC | 3.2625 | 1.7975 | 150000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 15:15:04 UTC | 3.2625 | 1.7975 | 150000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 14:45:04 UTC | 3.2639 | 1.7961 | 150000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 14:15:03 UTC | 3.2639 | 1.7961 | 200000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 13:45:03 UTC | 3.2639 | 1.7961 | 200000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 13:15:03 UTC | 3.2639 | 1.7961 | 200000 |
PROTARA THERAPEUTIC INC TARA | 2023-06-06 12:45:05 UTC | 3.2639 | 1.7961 | 200000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|